Extended anti-HER2 therapy in early breast cancer: longer beats shorter?

Refae, Sadal; Pistilli, Barbara; Delaloge, Suzette

Refae, Sadal; Pistilli, Barbara; Delaloge, Suzette.

Affiliation

Refae S; Departments of Cancer Medicine and Breast Oncology, Gustave Roussy, Villejuif, France.

Curr Opin Oncol ; 28(6): 469-475, 2016 11.

Article in En | MEDLINE | ID: mdl-27606697

Subject(s)

Breast Neoplasms/drug therapy; Breast Neoplasms/enzymology; Protein Kinase Inhibitors/administration & dosage; Receptor, ErbB-2/antagonists & inhibitors; Trastuzumab/administration & dosage; Antineoplastic Agents/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Chemotherapy, Adjuvant; Female; Humans; Randomized Controlled Trials as Topic

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Protein Kinase Inhibitors / Trastuzumab Type of study: Clinical_trials Limits: Female / Humans Language: En Journal: Curr Opin Oncol Journal subject: NEOPLASIAS Year: 2016 Document type: Article Affiliation country: France Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links